RT Journal Article SR Electronic T1 Sequential 99mTc-Hydrazinonicotinamide-Annexin V Imaging for Predicting Response to Chemotherapy JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1813 OP 1818 VO 47 IS 11 A1 Rottey, Sylvie A1 Slegers, Guido A1 Van Belle, Simon A1 Goethals, Ingeborg A1 Van de Wiele, Christophe YR 2006 UL http://jnm.snmjournals.org/content/47/11/1813.abstract AB This study was undertaken to evaluate changes in relative 99mTc-hydrazinonicotinamide (HYNIC)-annexin V tumor uptake over time in patients undergoing chemotherapeutic treatment at baseline and at 5–7 h and 40–44 h after treatment initiation. Imaging results are related to clinical outcomes, as assessed with response evaluation criteria in solid tumors (RECIST). Methods: We prospectively included 20 patients (11 men and 9 women; mean age, 59.8 y; range, 22–75 y) scheduled for chemotherapy (n = 19) or bisphosphonate treatment (n = 1). Curable disease was present in 5 patients. The other patients had metastatic disease and were treated in a palliative setting. Three of the 20 enrolled patients were excluded from analysis: 1 patient ultimately refused the proposed chemotherapy treatment; because of difficulties with the labeling procedure, 1 patient did not receive a pretreatment scan; and 1 patient presented with an allergic reaction (rash and nausea) to the 99mTc-HYNIC-annexin V formulation. The remaining 17 patients underwent 3 scintigraphic scans with 99mTc-HYNIC-annexin V: before treatment and 5–7 h and 40–44 h after treatment initiation. The tumor response was evaluated with RECIST and related to observed changes in the ratios of tumor activity to background activity for the largest known lesion; values exceeding 25% the baseline value on either the 5- to 7-h scan or the 40- to 44-h scan were considered significant. Results: With the proposed sequential imaging protocol and a 25% change threshold, responders to treatment could be separated from nonresponders with a 94% accuracy (16/17 patients). Conclusion: Sequential 99mTc-HYNIC-annexin V imaging may allow for assessment of the response to chemotherapy within 3 d after treatment initiation.